Trial Profile

Three-part PK and PD study of AXN-027

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AXN 027 (Primary)
Indications Epilepsy; Neuropathic pain; Spinal cord injuries
Focus Proof of concept; Therapeutic Use
Sponsors AXONIS Therapeutics

Most Recent Events

29 Jun 2026 Status changed from planning to recruiting.
05 Nov 2024 New trial record
30 Oct 2024 According to Axonis Therapeutics media release, company aanounced the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance AXN-027, through clinical proof-of-concept in patients.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com